Skip to main content

Table 5 Cox proportional hazards univariate modeling for time to treatment failure and overall survival

From: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Variable Time to treatment failure Overall survival
  Hazard ratio (95% CI) P valuea Hazard ratio (95% CI) P valuea
Univariate modeling
   Age >50 years 0.59 (0.42–0.83) 0.0051 0.64 (0.46–0.89) 0.041
   Performance status: 0 versus 1 or 2 1.30 (0.95–1.78) 0.11 1.41 (1.03–1.94) 0.031
   ER positive 0.78 (0.56–1.08) 0.13 0.61 (0.43–0.84) 0.0029
   PR positive 0.72 (0.51–1.00) 0.53 0.71 (0.51–1.00) 0.049
   ER/PR positive 0.72 (0.51–1.00) 0.53 0.62 (0.44–0.86) 0.0048
   Number of metastatic sites: 0 to 2 versus 3+ 1.72 (1.03–2.88) 0.37 1.10 (0.66–1.82) 0.72
   Disease-free interval: ≤2 years versus >2 years 0.72 (0.52–1.00) 0.49 0.81 (0.59–1.12) 0.20
   Prior adjuvant chemotherapy 0.87 (0.63–1.20) 0.39 0.93 (0.68–1.29) 0.67
   HER2 positive by CB11 1.44 (0.97–2.15) 0.68 1.34 (0.91–1.99) 0.41
   HER2 positive by FISH 1.22 (0.85–1.76) 0.29 1.24 (0.86–1.79) 0.25
   HER2 by HercepTest: 0–1 versus 2–3 1.02 (0.73–1.43) 0.90 1.04 (0.74–1.46) 0.83
   HER2 by HercepTest: 0–2 versus 3 1.34 (0.91–1.98) 0.14 1.11 (0.76–1.64) 0.59
Multivariate modeling
   Age >50 years 0.99 (0.97–1.00) 0.045 0.99 (0.97–1.00) 0.10
   ER/PR positive 1.28 (0.89–1.82) 0.18 1.55 (1.08–2.22) 0.017
   HER2 negative on HercepTest: 0–1 versus 2–3 0.97 (0.68–1.40) 0.88 0.93 (0.65–1.35) 0.71
  1. a P values were calculated using the log-rank test. CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization; PR, progesterone receptor.